News - Page 8 of 13 - Leukaemia Care

23rd March 2021

Reflecting on the last year

Today is National Day of Reflection, in this article we look back on the last 12 months and showcase what we have achieved.

18th March 2021

Acalabrutinib to become a treatment option for certain groups of CLL patients in England

The National Institute for Health and Care Excellence (NICE) have made recommendations for acalabrutinib to become a treatment option for certain groups of chronic lymphocytic leukaemia (CLL) patients in England.

17th March 2021

Leukaemia Care’s response to the pausing of shielding on the 31stof March

Today, it was confirmed that shielding in England will once again be paused on the 31stof March. Here is our response to the news

11th March 2021

Call for review of COVID vaccine timings for blood cancer patients

Following the publication of emerging evidence that the Pfizer COVID vaccines are less effective for cancer patients after a single dose, the Blood Cancer Alliance (BCA) has today written to the Joint Committee on Vaccination and Immunisation (JCVI) asking them to review the case for a reduction in the 12-week delay between vaccination doses for blood cancer patients.

7th December 2020

SMC approves venetoclax with obinutuzumab for some patients with untreated CLL

The Scottish Medicines Consortium (SMC) have today made recommendations for venetoclax plus obinutuzumab to become a treatment option for certain groups of chronic lymphocytic leukaemia (CLL) patients in Scotland.

10th November 2020

NICE approves venetoclax with obinutuzumab for patients with untreated CLL

The National Institute for Health and Care Excellence (NICE) have made recommendations for venetoclax plus obinutuzumab as an option for chronic lymphocytic leukaemia (CLL) patients in England.

7th September 2020

The Scottish Medicine Consortium (SMC) approves gilteritinib for relapsed/refractory AML patients in Scotland

The Scottish Medicine Consortium (SMC) has recommended the use of gilteritinib for patients who have relapsed or refractory acute myeloid leukaemia (AML) with a FLT3 mutation. Find out what this means for patients in Scotland here.

4th September 2020

1 in 10 wouldn’t contact GP with ANY symptoms of blood cancer

A poll of more than 2,000 UK adults has revealed that 1 in 10 of people would not visit the GP with the symptoms that could indicate a leukaemia.

1st September 2020

Leukaemia Care statement regarding Coronavirus – COVID-19

Statement from Leukaemia Care regarding Coronavirus - COVID-19

16th July 2020

NICE approves gilteritinib for treating relapsed or refractory acute myeloid leukaemia

The National Institute of Health and Care Excellence (NICE) have today made an announcement for the recommendation of gilteritinib as an option in adults with relapsed or refractory FLT3-positive acute myeloid leukaemia (AML).